$1.12
+0.00 (+0.00%)
Open$1.10
Previous Close$1.12
Day High$1.17
Day Low$1.06
52W High$35.24
52W Low$24.14
Volume—
Avg Volume610.6K
Market Cap9.33M
P/E Ratio28.34
EPS$0.96
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,591.1% upside
Current
$1.12
$1.12
Target
$30.14
$30.14
$22.58
$30.14 avg
$41.69
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.48M | 2.49M | 2.71M |
| Net Income | -380,025 | -467,867 | -467,071 |
| Profit Margin | -15.3% | -18.8% | -17.2% |
| EBITDA | -552,767 | -558,041 | -685,415 |
| Free Cash Flow | -221,579 | -328,689 | -323,480 |
| Rev Growth | +22.9% | +23.1% | -7.6% |
| Debt/Equity | 0.29 | 0.26 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |